EUnetHTA JA3 WP4 - Other technologies, OTCA16

Review by external experts of the 2nd draft Project Plan for Bioresorbable stents in cardiovascular indications (coronary artery disease)



Comments should be submitted not later than Weekday 23/07/2018

Please use this form for submitting your comments and please return to Judit Erdos:

- 1. Please put each new comment in a new row.
- 2. Please insert the page number and section number on which your comment applies. If your comment relates to the document as a whole, please put 'general' in this column.
- 3. Please provide a description of your comment as specific as possible and preferably also provide a suggestion for rewording. If you wish to draw our attention to published literature, please supply the full reference.

The draft Project Plan of the Rapid Assessment on Bioresorbable stents in cardiovascular indications (coronary artery disease) is open to review between 13/07/2018 and 23/07/2018.

Comment	Page	Line/	Comment and suggestion for rewording	Character of	Author's reply
from	number	section	Please insert each new comment in a new row.	comment	
Insert your name and	Insert	number		• 'major'ª=1	
organisation	'general' if your			• 'minor' ^b = 2	
	comment			• 'linguistic' ^c =3	
	relates to			Please indicate your choice by writing the	
	the whole document			according number in	
	document			this field, e.g. for	
-				major choose "1".	144
Dr. Schuchlenz			Patients with acute coronary heart disease clearly benefit from		We agree.
Scriucilleriz			an invasive treatment with PCI using drug eluting stents.		
Dr.			Co for the heat management atrategy for nationts with stable		Wo agree
Schuchlenz			So far the best management strategy for patients with stable		We agree.
			ischemic heart disease (invasive strategy (INV) with cardiac		
			catheterization followed by revascularization plus optimal		
			medical therapy (OMT) or to a conservative strategy (CON) of		
			OMT, with cardiac catheterization and revascularization		

Please add extra rows as needed.

^a "major": the comment points to a highly relevant aspect and a thorough answer is expected from the author(s)

^b "minor": the comment does not necessarily have to be answered in a detailed manner

^c"linguistic": grammar, wording, spelling or comprehensibility

EUnetHTA JA3 WP4 - Other technologies, OTCA16 Review by external experts of the 2nd draft Project Plan for Bioresorbable stents in cardiovascular indications (coronary artery disease)



Comments should be submitted not later than Weekday 23/07/2018

					EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT
Comment	Page	Line/	Comment and suggestion for rewording	Character of	Author's reply
from	number	section	Please insert each new comment in a new row.	comment	
Insert your	Insert	number		• 'major'a=1	
name and organisation	'general'			• 'minor' ^b = 2	
organioación	if your comment			• 'linguistic' =3	
	relates to			Please indicate your	
	the whole			choice by writing the	
	document			according number in this field, e.g. for	
				major choose "1".	
			reserved for those who fail OMT) has not been answered		
			clearly. This issue is actually determined by the ISCHEMIA trial.		
Dr.			Therefore a subgroup analysis evaluating the different		We will carry out this subgroup
Schuchlenz			indications for stent implantations would absolutely make sense.		analysis if appropriate data are
					available.

Please add extra rows as needed.

^a "major": the comment points to a highly relevant aspect and a thorough answer is expected from the author(s) ^b "minor": the comment does not necessarily have to be answered in a detailed manner

cullinguistic": grammar, wording, spelling or comprehensibility